PATTI JOSEPH M 4

What Happened

• Patti Joseph, a director of Armata Pharmaceuticals, was granted 25,640 derivative shares (reported as a stock option award) on March 9, 2026. The filing reports a price of $0.00 and a reported value of $0 for the transaction. This is a grant/award (compensation), not a purchase or sale.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (timely filing).
• Transaction type/code: Grant/A (derivative instrument — stock options).
• Shares/options granted: 25,640; reported price/value: $0.00 / $0 (per the filing).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The stock options "will vest in full on March 9, 2027, subject to continuous service through the vesting date" (F1).
• No indication in the filing of an immediate exercise, sale, tax withholding, or a 10b5-1 plan.

Context

• This is a typical director compensation award intended for retention; it does not represent an open‑market purchase or sale. Because the options vest one year after grant (subject to continued service), they are not immediately tradable or indicative of instant cash value.